-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

605. Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases: Poster II

Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 6, 2015: 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Hun Ju Lee, MD1*, Miguel Gallardo, PhD2*, Xiaorui Zhang, BS2*, Huaxian Ma, BS2*, Alfonso Quintas-Cardama, MD2, Yuan Qi3*, Xiaoping Su, PhD4* and Sean M. Post, PhD2

1Department of Lymphoma & Myeloma, MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, MD Anderson Cancer Center, Houston, TX
3Department of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX
4Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX

Yo-Ting Tsai, MS1, Gerard Lozanski, MD2*, Amy M. Lehman, MAS3*, Ellen Sass4*, Erin K. Hertlein, PhD5, Santosh Salunke1*, Ching-Shih Chen, PhD1*, Michael R. Grever, MD5, John C. Byrd, MD6 and David M. Lucas, PhD6

1College of Pharmacy, The Ohio State University, Columbus, OH
2Pathology, The Ohio State University, Columbus, OH
3Center for Biostatistics, Department of Bioinformatics, The Ohio State University, Columbus, OH
4Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH
5Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH
6Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

Andrea Ghelli Luserna Di Rora1*, Ilaria Iacobucci, PhD2*, Enrica Imbrogno3*, Enrico Derenzini, MD3*, Anna Ferrari, PhD4*, Viviana Guadagnuolo, PhD4*, Valentina Robustelli3*, Simona Soverini5, Cristina Papayannidis, MD, PhD6, Maria Chiara Abbenante, MD4*, Michele Cavo, MD2* and Giovanni Martinelli, MD, PhD6

1DIMES, Department of Hematology and Medical Sciences “L. and A. Seràgnoli”, Bologna, Italy, Bologna, Italy
2"Seràgnoli" Institute of Hematology, University of Bologna, Bologna, Italy
3DIMES, Department of Hematology and Medical Sciences “L. and A. Seràgnoli”, University of Bologna, Bologna, Italy
4University of Bologna, Bologna, Italy
5Institute of Hematology, S.Orsola-Malpighi University Hospital, Bologna, Italy
6Bologna University School of Medicine, Bologna, Italy

Rosaria De Filippi, MD, PhD1,2*, Michele Cillo, ScD1*, Stefania Crisci, ScD1*, Sara Mele, BS1*, Serena Zanotta, ScD1*, Angela De Monaco, ScD1*, Domenico Galati, MD1*, Giancarla Iaccarino, ScD1*, Raffaele Di Francia, ScD1*, Emanuela Morelli, MD1*, Gianpaolo Marcacci, MD1*, Cristina Becchimanzi, MD1*, Attilio Guarini, MD3*, Ferdinando Frigeri, MD, PhD1*, Gaetano Corazzelli, MD1* and Antonello Pinto, MD1*

1Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Naples, Italy
2Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
3Hematology, Ospedale oncologico 'Giovanni Paolo II', I.R.C.C.S., Bari, Italy

Meirong Zang1*, Fengyan Jin2*, Lanting Liu1*, Gang An, MD.PhD1*, Xiaoqi Qin, MD.1*, Xiaoyan Feng1*, Yan Xu, MD, PhD1*, Mu Hao, MD, PhD1*, Wen Zhou, Ph.D1,3* and Lugui Qiu, MD, PhD1

1State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
2Cancer Center, The First Hospital of Jilin University, Changchun, China
3Cancer Research Institute, Central South University; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education;Key Laboratory of Carcinogenesis, National Health and Family Planning Commission, Changsha, China

Rosaria De Filippi, MD, PhD1,2*, Stefania Crisci, ScD2*, Michele Cillo, ScD2*, Sara Mele, BS2*, Angela De Monaco, ScD2*, Domenico Galati, MD2*, Serena Zanotta, ScD2*, Gaetana Capobianco, MD2*, Francesco Volzone, MD2*, Manuela Arcamone, MD2*, Piera Maiolino, PharmD3*, Mariangela Saggese, PharmD2*, Gaetano Corazzelli, MD2*, Ferdinando Frigeri, MD, PhD2*, Thomas Mehrling, MD, PhD4* and Antonello Pinto, MD2*

1Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
2Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Naples, Italy
3Pharmacy Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Naples, Italy
4Mundipharma-EDO GmbH, Basel, Switzerland

Rick Sorensen, BS*, Sarah Meadows*, Anella Yahiaoui, BS*, Li Li, PhD, Peng Yue, PhD*, Adam Kashishian, BS*, Christophe Queva, PhD and Stacey Tannheimer, PhD*

Gilead Sciences, Foster City, CA

Luigi Rigacci1*, Gabriele Perrone2*, Stefania Nobili2*, Sofia Kovalchuk1*, Benedetta Puccini1*, Federica Lancia1*, Renato Tassi2*, Marco Brugia2*, Ida Landini2*, Lara Mannelli1*, Gemma Benelli1*, Cristina Napoli2*, Emanuele Cencini3*, Alberto Fabbri4*, Lorenzo Iovino5*, Mario Petrini5, Silvia Birtolo6*, Alessandro Melosi7*, Varesco Martini8*, Simone Santini9*, Carla Breschi10*, Paolo Bernardeschi11*, Carmelo Bengala12*, Alberto Bosi, MD1 and Enrico Mini2*

1Hematology Department, University and Hospital Careggi, Firenze, Italy
2Dipartimento di Scienze della Salute, University of Florence, Firenze, Italy
3Hematology Unit, Ospedale Santa Maria alle Scotte and University of Siena, Siena, Italy
4Az. Ospedaliera Universitaria Senese, Siena, Italy
5Hematology Department, University of Pisa, Pisa, Italy
6Oncology Department, Hospital, Pescia, Italy
7Oncology, Hospital, Lucca, Italy
8Oncology, Hospital, Firenze, Italy
9Oncology, Hospital, Prato, Italy
10Oncology, Hospital, Pistoia, Italy
11Oncology, Hospital, Empoli, Italy
12Oncology, Hospital, Grosseto, Italy

Paul J. Hengeveld, B.Sc.1,2*, Geoffrey M. Matthews, PhD1*, Yiguo Hu, MD, PhD1*, Michal Sheffer, PhD1*, Megan A. Bariteau, BSc1*, Haley I. Poarch1*, Eugen Dhimolea, PhD1* and Constantine S Mitsiades, MD, PhD1

1Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Department of Hematology, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands

Joan Ballesteros1, Lydia Scarfo2*, Mattias Mattsson3*, Aliki Xochelli4*, Pamela Ranghetti5*, Daniel Primo1*, Alicia Robles1*, Julian Gorrochategui1*, Joaquin Martinez-Lopez6*, Javier De la Serna6, Marcos González, MD, PhD7*, Veerendra Munugalavadla8, Richard Rosenquist9, Kostas Stamatopoulos4*, Christophe Quéva, Ph.D.8* and Paolo Ghia, MD, PhD10

1Vivia Biotech, Madrid, Spain
2Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy
3Uppsala University, Uppsala, Sweden
4Institute of Applied Biosciences, CERTH, Thessaloniki, Greece
5Università Vita-Salute San Raffaele and Ospedale San Raffaele, Milano, Italy
6Hospital Universitario 12 de Octubre, Madrid, Spain
7Hospital Clínico Universitario de Salamanca, Salamanca, Spain
8Gilead Sciences, Foster City, CA
9Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
10Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milano, Italy

Keith J. August, MD, MS1, Leon van Haandel, PhD2* and J. Steven Leeder, PharmD, PhD2*

1Division of Hematology/Oncology, Children's Mercy Hospital, Kansas City, MO
2Division of Clinical Pharmacology and Therapeutic Innovation, Children's Mercy Hospital, Kansas City, MO

Marsha L. Crochiere, PhD1*, Stefan Hannus, PhD2*, Kerrin Hansen2*, Frank Becker, PhD2*, Joel Ellis, PhD1*, Margaret S. Lee, PhD1 and Yosef Landesman, PhD1*

1Karyopharm Therapeutics Inc., Newton, MA
2Intana Bioscience GmbH, Planegg/Martinsried, Germany

Yana Pikman, MD1, Andrew Furman, BA2*, Emily S. Lee2*, Andrew E. Place, MD, PhD1, Gabriela Alexe, PhD2*, Rebecca Modiste, RT(N), LAT3*, Prafulla Gokhale, PhD3*, Sunkyu Kim, PhD4*, Lewis B. Silverman, MD1 and Kimberly Stegmaier, MD1

1Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA
2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
3Dana-Farber Cancer Institute, Boston, MA
4Novartis Institute for Biomedical Research, Cambridge, MA

*signifies non-member of ASH